Kaczala, F. and Blum, E.S. (2015). The occurrence of veterinary pharmaceuticals in the environment: a review. Curr. Anal. Chem. 12(3): 169–182. doi: 10.2174/1573411012666151009193108.11 11 Escher, B.I. and Fenner, K. (2011). Recent advances in environmental risk assessment of transformation products. Environ. Sci. Technol. 45(9): 3835–3847. doi: 10.1021/es1030799.
12 12 Evgenidou, E.N., Konstantinou, I.K., and Lambropoulou, D.A. (2015). Occurrence and removal of transformation products of PPCPs and illicit drugs in wastewaters: a review. Sci. Total Environ. 505: 905–926. doi: 10.1016/j.scitotenv.2014.10.021.
13 13 Celiz, M., Tso, J.D., and Aga, D.S. (2009). Pharmaceutical metabolites in the environment: analytical challenges and ecological risks. Environ. Toxicol. Chem. 28(12): 2473–2484. doi: 10.1897/09-173.1.
14 14 Yin, L., Wang, B., Yuan, H., Deng, S., Huang, J., Wang, Y., and Yu, G. (2017). Pay special attention to the transformation products of PPCPs in environment. Emerg. Contam. 3(2): 69–75. doi: 10.1016/j.emcon.2017.04.001.
15 15 Besse, J.P., Latour, J.F., and Garric, J. (2012). Anticancer drugs in surface waters. What can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs? Environ. Int. 39(1): 73–86. doi: 10.1016/j.envint.2011.10.002.
16 16 Madikizela, L.M., Ncube, S., Tutu, H., Richards, H., Newman, B., Ndungu, K., and Chimuka, L. (2020). Pharmaceuticals and their metabolites in the marine environment: sources, analytical methods and occurrence. Trends Environ. Anal. Chem. 28: e00104. doi: 10.1016/j.teac.2020.e00104.
17 17 Godoi, F.C., Prakash, S., and Bhandari, B.R., (2019). Final report The database “Pharmaceuticals in the Environment” – update and new analysis. Germany: German Environmental Agency, Umwelt Bundesamt, p. 103. Report No.: 67/2019.
18 18 Commission Implementing Decision (EU) 2015/495 of 20 March 2015 establishing a watch list of substances for Union-wide monitoring in the field of water policy pursuant to Directive 2008/105/EC of the European Parliament and of the Council.
19 19 Commission Implementing Decision (EU) 2018/840 of 5 June 2018 establishing a watch list of substances for Union-wide monitoring in the field of water policy pursuant to Directive 2008/105/EC of the European Parliament and of the Council and repealing Comm.
20 20 Commission Implementing Decision (EU) 2020/1161 of 4 August 2020 establishing a watch list of substances for Union-wide monitoring in the field of water policy pursuant to Directive 2008/105/EC of the European Parliament and of the Council.
21 21 European Medicines Agency (2006). Guideline on the Environmental Risk Assessment of Medical Products for Human Use. London: European Medicines Agency. Report No.: EMEA/CHMP/SWP/4447/00.
22 22 Guideline on the Environmental Risk Assessment for Veterinary Medicinal Products in Support of the VICH GL6 and GL 38. London: European Medicines Agency; 2008, 77 p. Report No.: EMEA/CVMP/ERA/418282/2005-Rev.1.
23 23 Ankley, G.T., Brooks, B.W., Huggett, D.B., and Sumpter, J.P. (2007). Repeating history: Pharmaceuticals in the environment. Environ. Sci. Technol. 15: 8211–8217. doi: 10.1021/es072658j.
24 24 Schmitt, H., Boucard, T., Garric, J., Jensen, J., Parrott, J., Péry, A., Rӧmbke, J., Straub, J.O., Hutchinson, T.H., Sanchez-Argüello, P., Wennmalm, A., and Duis, K. (2010). Recommendations on the environmental risk assessment of pharmaceuticals: Effect characterization. Integr. Environ. Assess. Manag. 6: 588–602. doi: 10.1897/IEAM_2009-053.1.
25 25 Tarazona, J.V., Escher, B.I., Giltrow, E., Sumpter, J., and Knacker, T. (2010). Targeting the environmental risk assessment of pharmaceuticals: Facts and fantasies. Integr. Environ. Assess. Manag. 6: 603–613. doi: 10.1897/IEAM_2009-052.1.
26 26 Męczykowska, H., Kobylis, P., Stepnowski, P., and Caban, M. (2017). Calibration of passive samplers for the monitoring of pharmaceuticals in water-sampling rate variation. Crit. Rev. Anal. Chem. 47(3): 204–222. doi: 10.1080/10408347.2016.1259063.
27 27 Martínez Bueno, M.J., Herrera, S., Munaron, D., Boillot, C., Fenet, H., Chiron, S., and Gómez, E. (2016). POCIS passive samplers as a monitoring tool for pharmaceutical residues and their transformation products in marine environment. Environ. Sci. Pollut. Res. 23(6): 5019–5029. doi: 10.1007/s11356-014-3796-5.
28 28 Rimayi, C., Chimuka, L., Gravell, A., Fones, G.R., and Mills, G.A. (2019). Use of the Chemcatcher® passive sampler and time-of-flight mass spectrometry to screen for emerging pollutants in rivers in Gauteng Province of South Africa. Environ. Monit. Assess. 191(6): 388. doi: 10.1007/s10661-019-7515-z.
29 29 Jakubus, A., Godlewska, K., Gromelski, M., Jagiello, K., Puzyn, T., Stepnowski, P., and Paszkiewicz, M. (2019). The possibility to use multi-walled carbon nanotubes as a sorbent for dispersive solid phase extraction of selected pharmaceutical and their metabolites: Effect of extraction condition. Microchem. J. 146: 1113–1125. doi: 10.1016/j.microc.2019.02.051.
30 30 Męczykowska, H., Kobylis, P., Stepnowski, P., and Caban, M. (2017). Ionic liquids for the passive sampling of sulfonamides from water – applicability and selectivity study. Anal. Bioanal. Chem. 409(16): 3951–3958. doi: 10.1007/s00216-017-0342-6.
31 31 Caban, M., Męczykowska, H., and Stepnowski, P. (2016). Application of the PASSIL technique for the passive sampling of exemplary polar contaminants
